Trials / Completed
CompletedNCT02449577
Identification of Biomarkers for Acute Intake of Beer and Alcohol and Acute Effects on Plasma and Insulin Response
Metabolomics in Beer Research: Identification of Biomarkers for Acute Intake of Beer and Alcohol in Individuals With a High or Low Habitual Intake, and Acute Effects on Plasma Glucose and Insulin Response Compared to Regular Soda
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- University of Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to identify biomarkers for acute intake of beer and alcohol in individuals with a high or low habitual intake. Furthermore, we wish to identify compounds and metabolites in different types of beer and alcohol, which can serve as compliance markers for intake under the test conditions (blood tests and urine samples). We also wish to determine the acute effects of these beverages on plasma glucose and insulin response, compared to regular soda.
Detailed description
The study is designed as a randomized, 4-way single-blinded cross-over intervention study. The participants are randomized individually to the order by which they shall receive 4 test meals. There will be implemented a standardized lunch which includes respectively 1) Light/alcohol-free (Tuborg Super Light 0,1% alcohol), 2) Regular lager (4,6% alcohol), 3) Strong beer(7,2% alcohol) and 4) a control drink without alcohol but with the same energy content (carbohydrate and protein) as the average of the other beverages ("sportsdrink"). Besides 330 ml of each test drink, each test meal consists of grilled cheese sandwiches (Tulip Food Company) and the amount of toast adjusted according to the type of drink served with each meal, so the content of macronutrients is the same in each meal. The study includes 16-20 participants, randomized as to which order they will receive the 4 test meals with a washout period of at least 6 days in between test days. Upon arrival the test persons are asked to urinate (baseline sample), and at the 1st visit they are then weighed, height is measured and body composition (bioimpedance) is measured. After resting briefly, a baseline blood sample is taken and blood pressure is measured (1st and 4th visit). 45 minutes after start of the test meal the first postprandial blood sample is taken, and again after 45, 120 and 180 minutes. Urine is collected again at 0-90 min, 90-180 min and 3-24 hours after the test meal. Participants are provided with containers and equipment for this purpose, and must submit samples on an ongoing basis to the Dept. of Nutrition, Exercise and Sports.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Beverage sequence ABCD | Participants receive test beverages in the randomised order ABCD |
| OTHER | Beverage sequence CADB | Participants receive test beverages in the randomised order CADB |
| OTHER | Beverage sequence DACB | Participants receive test beverages in the randomised order DACB |
| OTHER | Beverage sequence CBAD | Participants receive test beverages in the randomised order CBAD |
| OTHER | Beverage sequence ABDC | Participants receive test beverages in the randomised order ABDC |
| OTHER | Beverage sequence DABC | Participants receive test beverages in the randomised order DABC |
| OTHER | Beverage sequence DCAB | Participants receive test beverages in the randomised order DCAB |
| OTHER | Beverage sequence DBCA | Participants receive test beverages in the randomised order BDCA |
| OTHER | Beverage sequence ADCB | Participants receive test beverages in the randomised order ADCB |
| OTHER | Beverage sequence BADC | Participants receive test beverages in the randomised order BADC |
| OTHER | Beverage sequence ACDB | Participants receive test beverages in the randomised order ACDB |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2015-05-20
- Last updated
- 2015-05-20
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02449577. Inclusion in this directory is not an endorsement.